Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 8,161–8,220 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

University Hospital of Padua1 University Hospital of Parma1 University Hospital of Siena1 University Hospital of Southampton1 University Hospital of Southern Denmark, Aabenraa1 University Hospital of Tuebingen1 University Hospital of Wales1 University Hospital of Zurich1 University Hospital of the Canary Islands1 University Hospital of the Federal University of Juiz de Fora1 University Hospitals Birmingham NHS Foundation Trust1 University Hospitals Bristol and Weston1 University Hospitals Cleveland Medical Center Institutional Review Board1 University Hospitals Dorset NHS Foundation Trust1 University Hospitals Leuven1 University Hospitals Leuven and Antwerp1 University Hospitals Plymouth NHS Trust1 University Hospitals of Antwerp and Leuven1 University Hospitals of Leicester NHS Trust1 University Hospitals of Leuven and Antwerp1 University Hospitals of Morecambe Bay NHS Foundation Trust1 University Institute for Research in Primary Care1 University Maternity Hospital Limerick1 University Medical Center Mainz1 University Medical Center Utrecht1 University Medical Centre Greifswald1 University Medical Centre Hamburg-Eppendorf1 University Medicine Duisburg/Essen1 University SEM Committees1 University Sud Mediterranean 31 University Teaching Hospital of Kigali1 University hospital Erlangen1 University of Alberta1 University of Alberta Health Research Ethics Board-Health Panel1 University of Alcalá1 University of Antwerp1 University of Athens Medical School1 University of Barcelona1 University of Bari1 University of Basel1 University of Bedfordshire Institute for Health Research Ethics Committee1 University of Belgrade School of Dental Medicine EC1 University of Benin Teaching Hospital1 University of Birmingham Edgbaston Campus1 University of Bologna1 University of Bremen1 University of British Columbia Clinical Research Ethics Board1 University of Buea1 University of Calgary Conjoint Faculties Research Ethics Board1 University of California Cancer Centers1 University of California Cancer Research Coordinating Committee1 University of California Davis1 University of California Health system1 University of California Los Angeles Institutional Review Board1 University of California San Francisco Institutional Review Board1 University of California and Los Angeles1 University of California at Los Angeles1 University of California in San Francisco1 University of California, Irvine EyeMobile Pediatric Clinic1 University of California, San Francisco Institutional Review Board1

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 312 of 946

521 Correlative analysis of a phase I study of autologous activated NK Cells ± rhIL-15 in children and young adults with refractory solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

93.7%

National Cancer Institute NCI rhIL-15 solid tumors relapsed/refractory solid tumors NK cell immunotherapies cyclophosphamide

…his study was approved by the Institutional Review Board of the National Cancer Institute (NCI) at the NIH, approval number 13-C-0152, and was conducted …

522 A clinical study on iNeo-Vac-P01: a personalized neoantigen immunotherapy for postoperative recurrence prevention in pancreatic cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

95.3%

Zhejiang Provincial People’s Hospital iNeo-Vac-P01 pancreatic ductal adenocarcinoma (PDAC)

…n-label, single-arm clinical trial ( NCT04810910), conducted at Zhejiang Provincial People’s Hospital, enrolled PDAC patients who initiated treatment with iNeo-Vac-P…

536 Phase 1 trial of tumor-infiltrating lymphocyte (TIL) therapy in recurrent glioblastoma: A single-center experience using cells derived from primary surgical specimens

jitc · abstract · 2025-11-04 · 2 matching annotations

97.5%

Second Affiliated Hospital of Soochow University The Second Affiliated Hospital of Soochow University cyclophosphamide hydroxychloroquine Glioblastoma left frontal lobe glioblastoma sintilimab Innovent GB

… open-label, nonrandomized clinical trial ( NCT04943913) at the Second Affiliated Hospital of Soochow University to evaluate the safety and efficacy of TIL therapy in recurrent…

537 Targeting diffuse intrinsic pontine glioma with IL-7Rα-enhanced B7-H3 (CMD03) chimeric antigen receptor T cell: preliminary results from phase 1 clinical trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.0%

Chulalongkorn University Cancer Immunol Immunother dexamethasone CMD03 anakinra B7-H3 Diffuse intrinsic pontine glioma (DIPG)B7-H3-targeting DIPG

…DIPG ( NCT06221553). Approval was granted by the IRB committee, Chulalongkorn University (COA#1647/2024). Dose levels include 1×107, 3×107, and 1×108 CA…

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

jitc · abstract · 2025-11-04 · 2 matching annotations

79.9%

Voabil et al.NCT05478538 αPD-1 αPD-L1 αCTLA-4

…ovide external validation of a weighted classifier published by Voabil et al.1 for predicting response to PD-1 blockade. Additionally, we tra…

552 Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematological malignancies: Initial results from multi-institutional first-in-human (FIH) trials

jitc · abstract · 2025-11-04 · 2 matching annotations

98.3%

Indiana University University of Miami FDA AML bendamustine acute myeloid leukemias chronic myelomonocytic leukemia fludarabine/cyclophosphamide TCM venetoclax+3 more

…CT06197672Ethics Approval The study obtained ethics approval by Indiana University and University of Miami IRB and participants gave informed cons…

553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis

jitc · abstract · 2025-11-04 · 2 matching annotations

94.1%

Baylor College of Medicine BCM graft-versus-host disease B cell malignancies IL-15 ALL-1 NHL-2 ALL-3

…al This study was approved by the Institutional Review Board at Baylor College of Medicine (BCM; H-44526).…

556 Transposon-based BAFF CAR-T cells (LMY-920) for treatment of non-hodgkin lymphoma (NHL), chronic lymphocytic lymphoma (CLL) and multiple myeloma (MM)

jitc · abstract · 2025-11-04 · 2 matching annotations

92.2%

Case Comprehensive Cancer Center Cleveland Clinic’s Institutional Review Board fludarabine lymphoma myeloma cyclophosphamide LMY-920 systemic lupus erythematosus MM DLBCL+2 more

…06916767Ethics Approval The study obtained ethics approval from Case Comprehensive Cancer Center, Cleveland Clinic’s Institutional Review Board (24-424/MOD01553…

560 Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in bilateral lung transplantation: case series

jitc · abstract · 2025-11-04 · 2 matching annotations

97.1%

Northwestern Memorial Hospital Northwestern University durvalumab atezolizumab bilateral non-small cell lung cancer toripalimab nivolumab COPD cemiplimab colorectal cancer+4 more

…o underwent bilateral orthotopic lung transplantation (BOLT) at Northwestern Memorial Hospital (Sep 2021-May 2025) after at least one cycle of ICI therapy. Pa…

580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

86.5%

Cancer Res 2025 BAL0891 tislelizumab triple-negative breast cancer TTK-CS-101

…2164. https://doi.org/10.1158/1538-7445.AM2025-2164Wang, et al. Cancer Res 2025;85(8_Supplement_1):2169. https://doi.org/10.1158/1538-7445.AM20…

582 First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

80.1%

Cedars-Sinai Medical Center Stephenson Cancer Center CRB-601 ovarian cancer head and neck squamous cell carcinoma melanoma

…University Hospital Cleveland University Hospitals IRB 20241088 Cedars-Sinai Medical Center Cedars-Sinai Office of Research Compliance and Quality Improvem…

583 Intrathecal PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from solid tumors: preliminary results from a phase I/II study (NCT 06462222)

jitc · abstract · 2025-11-04 · 2 matching annotations

91.2%

Guangzhou Medical University Affiliated Huizhou Hospital pemetrexed non-small cell lung cancer solid tumors small cell lung cancer Intrathecal PD-1 inhibitor breast cancer involved-field radiotherapy leptomeningeal metastases+1 more

… Institutional Review Board of the Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China (Approval number: 2024-KY-029-01). Informed con…